Description
The global semaglutide and tirzepatide API CDMO market was valued at USD 1.5 billion in 2025 and is projected to reach USD 3.9 billion by 2032, registering a CAGR of 14.6% during the forecast period. The market comprises contract development and manufacturing organizations (CDMOs) engaged in the development, scale-up, and commercial production of active pharmaceutical ingredients (APIs) for semaglutide and tirzepatide, two leading incretin-based peptide therapeutics used in the treatment of type 2 diabetes and obesity. The unprecedented global demand for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists has created significant manufacturing capacity constraints, prompting pharmaceutical companies to increasingly outsource peptide synthesis and API production to specialized CDMOs with advanced peptide manufacturing capabilities.
Market growth is further supported by increasing investments in peptide manufacturing infrastructure, expansion of high-capacity solid-phase peptide synthesis (SPPS) facilities, and growing outsourcing of complex API manufacturing. The rapid commercialization of obesity therapeutics, expanding clinical pipelines of next-generation incretin therapies, and continuous investments in large-scale peptide manufacturing facilities are creating significant opportunities for API CDMOs. Companies are expanding automated peptide synthesis capabilities, purification technologies, analytical testing, and GMP manufacturing infrastructure to meet surging commercial demand. North America currently dominates the market due to its advanced pharmaceutical manufacturing ecosystem and presence of leading innovator companies, while Asia Pacific is expected to witness the fastest growth owing to increasing peptide manufacturing investments, cost-efficient production capabilities, and expansion of global CDMO operations.
Key Highlights of the Report
• By molecule, semaglutide accounts for the largest share of the global semaglutide and tirzepatide API CDMO market, supported by widespread commercialization for type 2 diabetes and obesity management and sustained global manufacturing demand.
• Tirzepatide is projected to witness the fastest growth, driven by expanding regulatory approvals, superior clinical outcomes in obesity treatment, and rapidly increasing commercial demand.
• By service, commercial API manufacturing dominates the market, reflecting increasing outsourcing of large-scale peptide production by innovator pharmaceutical companies.
• API process development and scale-up services continue to witness strong demand, supported by growing pipelines of next-generation peptide therapeutics and manufacturing optimization projects.
• By synthesis technology, solid-phase peptide synthesis (SPPS) accounts for the largest market share, owing to its widespread adoption for complex peptide API manufacturing.
• Hybrid and continuous peptide manufacturing technologies are expected to witness significant growth, driven by increasing emphasis on manufacturing efficiency, scalability, and cost optimization.
• By end user, pharmaceutical companies dominate the global market, reflecting increasing outsourcing of peptide API production to specialized CDMOs with advanced manufacturing expertise.
• Biotechnology companies are projected to register substantial growth, supported by increasing development of novel GLP-1, GIP, and multi-receptor agonist therapies.
• The unprecedented global demand for obesity and diabetes therapeutics remains one of the primary market drivers, creating sustained demand for high-capacity peptide API manufacturing infrastructure.
• Capacity expansion across peptide synthesis and purification facilities is accelerating, enabling CDMOs to address commercial-scale manufacturing requirements for semaglutide and tirzepatide APIs.
• Technological advancements in automated peptide synthesis, purification systems, and analytical characterization are improving manufacturing efficiency, product quality, and regulatory compliance.
• Growing strategic collaborations between pharmaceutical companies and CDMOs continue to strengthen the outsourcing landscape, supporting long-term supply security for GLP-1 therapeutics.
• By region, North America dominates the global semaglutide and tirzepatide API CDMO market, supported by extensive pharmaceutical R&D activities, advanced peptide manufacturing infrastructure, and high biologics manufacturing investments.
• Asia Pacific is projected to witness the fastest growth, driven by increasing investments in peptide API manufacturing, expansion of CDMO facilities, and competitive manufacturing capabilities across India and China.
• The competitive landscape is highly competitive, with leading CDMOs focusing on peptide manufacturing expansion, GMP facility development, strategic partnerships, and advanced synthesis technologies to strengthen their market position.
• Major companies continue investing in high-capacity peptide synthesis platforms, purification technologies, process automation, and regulatory-compliant manufacturing facilities to address rapidly growing global demand for semaglutide and tirzepatide APIs.
Key Company Profiles
• AmbioPharm
• Asymchem Laboratories
• Bachem
• BCN Peptides
• CordenPharma
• Lonza
• PolyPeptide Group
• WuXi STA (WuXi TIDES)
• CSBio
• GenScript
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
